Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer

Xiaomin Liu, Ping Wang, Caiyan Zhang and Zhongliang Ma _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:50209-50220. https://doi.org/10.18632/oncotarget.16854

Metrics: PDF 10931 views  |   HTML 12388 views  |   ?  


Xiaomin Liu1,*, Ping Wang1,*, Caiyan Zhang1 and Zhongliang Ma1

1Lab for Noncoding RNA and Cancer, School of Life Sciences, Shanghai University, 200444 Shanghai, China

*These authors contributed equally to this work

Correspondence to:

Zhongliang Ma, email: [email protected]

Keywords: epidermal growth factor receptor (EGFR), noncoding RNA, precision medicine, lung cancer

Received: October 11, 2016     Accepted: March 24, 2017     Published: April 05, 2017


Lung cancer is a leading cause of cancer mortality worldwide. In tumors, the important role of noncoding RNA regulatory networks has been more and more reveal. EGFR has been identified as an oncogenic driver of NSCLC, especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses. Studies have shown that EGFR plays significant roles in the progression of NSCLC. Subset analysis of the small proportion of patients with EGFR-mutant lung cancer showed a disease-free survival benefit, but was underpowered to detect a survival advantage. Herein, we highlight the progression of EGFR, noncoding RNA, and their roles in carcinogenesis. We also focus on anti-lung cancer drug development and EGFR-related drug resistance.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16854